Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
|Articles|October 15, 2021
Daily Medication Pearl: Risankizumab-rzaa (Skyrizi) for Plaque Psoriasis
Author(s)Saro Arakelians, PharmD
Risankizumab-rzaa treats moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Advertisement
Medication Pearl of the Day: Risankizumab-rzaa (Skyrizi)
Indication: Risankizumab-rzaa is an interleukin (IL)-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Insight:
- Dosing: 150 mg administered by subcutaneous injection at week 0, week 4, and every 12 weeks thereafter.
- Dosage form: Injection 150 mg/mL in each single-dose prefilled pen. Injection 150 mg/mL in each single-dose prefilled syringe. Injection 75 mg/0.83 mL in each single-dose prefilled syringe.
- Adverse events (AEs): Most common AEs (≥ 1%) are upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.
- Mechanism of action: Risankizumab-rzaa is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds to the p19 subunit of the IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.
- Manufacturer: Abbvie
Sources:
Advertisement
Related to this article
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds
5